Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Payables (2017 - 2025)

Historic Payables for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $13.6 million.

  • Innate Pharma's Payables fell 2026.22% to $13.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.6 million, marking a year-over-year decrease of 2026.22%. This contributed to the annual value of $17.1 million for FY2024, which is 658.28% down from last year.
  • Innate Pharma's Payables amounted to $13.6 million in Q2 2025, which was down 2026.22% from $17.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Payables registered a high of $32.7 million during Q4 2021, and its lowest value of $13.6 million during Q2 2025.
  • Over the past 5 years, Innate Pharma's median Payables value was $19.9 million (recorded in 2022), while the average stood at $20.1 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 9992.28% in 2021, then skyrocketed by 382.06% in 2023.
  • Over the past 5 years, Innate Pharma's Payables (Quarter) stood at $32.7 million in 2021, then plummeted by 34.73% to $21.3 million in 2022, then decreased by 14.17% to $18.3 million in 2023, then dropped by 6.58% to $17.1 million in 2024, then decreased by 20.32% to $13.6 million in 2025.
  • Its Payables stands at $13.6 million for Q2 2025, versus $17.1 million for Q4 2024 and $17.1 million for Q2 2024.